Bi/ond and bit.bio collaboration offers a significant advancement for DMD research and drug discovery.
30.04.2024
Nobel Laureate Thomas Südhof and bit.bio CEO Mark Kotter to lead fireside chat on programming human cells at SynBioBeta
bit.bio will participate in an engaging fireside chat at SynBioBeta 2024 featuring Nobel Laureate Thomas Südhof and bit.bio Founde...
Sifted 100 Report highlights bit.bio as one of Europe's fastest-growing companies
bit.bio featured as one of Europe's fastest-growing startups in Sifted.
bit.bio joins ‘Future Fifty’ as one of UK’s exciting tech companies
bit.bio selected to join the ‘Future Fifty’ 2024 cohort as one of the UK’s most exciting technology companies.
European Biotechnology feature: Biology as Software
bit.bio's CEO, envisions a new era of cell therapies, where cells themselves become intelligent drugs, precisely tailored to indiv...
bit.bio announces collaboration with The Michael J. Fox Foundation
bit.bio announce first project in multi-year collaboration agreement with The Michael J. Fox Foundation to generate products for r...
GEN synbio feature: bit.bio is retooling nature’s code
bit.bio's CEO, our cell programming approach and our products prominently covered in synthetic biology article.
bit.bio announced as inaugural partner of Ginkgo's Technology Network
Ginkgo Technology Network brings together over 25 partners across an array of capabilities including AI, genetic medicines, biolog...
Reprogramming Stars - featuring bit.bio CEO Mark Kotter
Editor-in-Chief Carlos-Filipe Pereira interviews our CEO for the Reprogramming Stars series in the journal Cellular Reprogramming.